Tobias Weissenbacher
Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study
Deniz M, Andergassen U, Steidl J, Trapp E, Fasching P, Häberle L, Beckmann M, Schneeweiss A, Schrader I, Janni W, Rack B, Jueckstock J, Kost B, deGregorio A, DeGregorio N, Bekes I, Widschwendter P, Schochter F, Ernst K, Scholz C, Bauer E, Aivazova-Fuchs V, Weissenbacher T, Friedl T. Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. Breast 2018; 44:81-89.
20.12.2018Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study
20.12.2018Breast 2018; 44:81-89
Deniz Miriam, Andergassen Ullrich, Steidl Julia, Trapp Elisabeth, Fasching Peter A, Häberle Lothar, Beckmann Matthias W, Schneeweiss Andreas, Schrader Iris, Janni Wolfgang, Rack Brigitte, Jueckstock Julia, Kost Bernd, deGregorio Amelie, DeGregorio Nikolaus, Bekes Inga, Widschwendter Peter, Schochter Fabienne, Ernst Kristina, Scholz Christoph, Bauer Emanuel Ca, Aivazova-Fuchs Viktoria, Weissenbacher Tobias, Friedl Thomas Wp
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
Schwentner L, Janni W, Kiechle M, Härtl K, Weissenbacher T, Friedl T, Huober J, Scholz C, Wischnik A, Forstbauer H, Rack B, Eichler M, Singer S, Harbeck N, Fink V. Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial. Breast 2016; 27:69-77.
04.04.2016Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
04.04.2016Breast 2016; 27:69-77
Schwentner Lukas, Janni Wolfgang, Kiechle Marion, Härtl Kristin, Weissenbacher Tobias, Friedl Thomas W P, Huober Jens, Scholz Christoph, Wischnik Arthur, Forstbauer Helmut, Rack Brigitte, Eichler Martin, Singer Susanne, Harbeck Nadia, Fink Visnja
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
Widschwendter P, Jueckstock J, Neugebauer J, Trapp E, Fasching P, Beckmann M, Schneeweiss A, Schrader I, Rack B, Janni W, Andergassen U, Kost B, Friedl T, Schwentner L, DeGregorio N, Jaeger B, Schramm A, Bekes I, Deniz M, Lato K, Weissenbacher T, Scholz C. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res 2015; 17:129.
18.09.2015The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
18.09.2015Breast Cancer Res 2015; 17:129
Widschwendter Peter, Jueckstock Julia, Neugebauer Julia, Trapp Elisabeth, Fasching Peter A, Beckmann Matthias W, Schneeweiss Andreas, Schrader Ines, Rack Brigitte, Janni Wolfgang, Andergassen Ulrich, Kost Bernd, Friedl Thomas Wp, Schwentner Lukas, DeGregorio Nikolaus, Jaeger Bernadette, Schramm Amelie, Bekes Inga, Deniz Miriam, Lato Krisztian, Weissenbacher Tobias, Scholz Christoph
Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies
Salmen J, Sohn C, Fehm T, Mohrmann S, Loehberg C, Hein A, Schulz-Wendtland R, Hartkopf A, Brucker S, Wallwiener D, Friese K, Hartmann A, Beckmann M, Janni W, Rom J, Heil J, Neugebauer J, Fasching P, Haeberle L, Huober J, Wöckel A, Rauh C, Schuetz F, Weissenbacher T, Kost B, Stickeler E, Klar M, Orlowska-Volk M, Windfuhr-Blum M, Rack B. Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. Breast Cancer Res Treat 2014; 148:143-51.
25.09.2014Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies
25.09.2014Breast Cancer Res Treat 2014; 148:143-51
Salmen Jessica, Sohn Christof, Fehm Tanja, Mohrmann Svjetlana, Loehberg Christian R, Hein Alexander, Schulz-Wendtland Ruediger, Hartkopf Andreas D, Brucker Sara Y, Wallwiener Diethelm, Friese Klaus, Hartmann Arndt, Beckmann Matthias W, Janni Wolfgang, Rom Joachim, Heil Joerg, Neugebauer Julia, Fasching Peter A, Haeberle Lothar, Huober Jens, Wöckel Achim, Rauh Claudia, Schuetz Florian, Weissenbacher Tobias, Kost Bernd, Stickeler Elmar, Klar Maximilian, Orlowska-Volk Marzenna, Windfuhr-Blum Marisa, Rack Brigitte